Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.

Inês Pires da Silva,Alexander M. Menzies,Felicity Newell,James S. Wilmott,Matteo S. Carlino,Peter M. Ferguson,Jarem Edwards,Andrew J. Spillane,Kerwin Shannon,Robyn P. M. Saw,John F. Thompson,Helen Rizos,Graham J. Mann,Peter Johansson,Nicholas K. Hayward,Richard A. Scolyer,Nic Waddell,Georgina V. Long

Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.

2019

Inês Pires da Silva
Alexander M. Menzies
Felicity Newell
James S. Wilmott
Matteo S. Carlino
Peter M. Ferguson
Jarem Edwards
Andrew J. Spillane
Kerwin Shannon
Robyn P. M. Saw
John F. Thompson
Helen Rizos
Graham J. Mann
Peter Johansson
Nicholas K. Hayward
Richard A. Scolyer
Nic Waddell
Georgina V. Long

9511Background: Several factors have been proposed as biomarkers for response to PD1 therapy, including tumor mutational burden (TMB), immune gene expression, PD-L1 expression and TILs, while few s...

Keywords:

Melanoma
Immunotherapy
Pathology
Oncology
Medicine
Internal medicine
Cancer research
Biomarker (medicine)
metastatic melanoma
combination immunotherapy
immune gene

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations